

## **REMARKS**

Applicant respectfully requests entrance of the amendments as detailed above in the above-referenced patent application.

### **Amendments to the Specification**

The amendments to the specification, as detailed above, merely seek to incorporate priority information and to modify the title to read: " Deazapurines and Uses Thereof". No new matter is added with these amendments.

### **Amendments to the Claims**


Applicant has canceled claims 33-59 and 61-87, and has amended claims 1, 29-32 and 60. Claims 2-28 and 88-100 remain unchanged. The proposed amendments do not introduce new matter. Specifically, claim 1 has been amended to replace the language "and pharmaceutically acceptable derivatives thereof" with "or pharmaceutically acceptable derivative thereof." Claims 29 and 60 have been re-written in dependent form, and are now dependent of claim 1. Finally, claims 30-32 have been amended to correct a typographical error.

### CONCLUSION

Applicant thanks the Examiner for his/her time and consideration. If a telephone conversation would help clarify any issues, or help expedite prosecution of this case, Applicant invites the Examiner to contact the undersigned at (617) 248-5150.

It is not believed that fees for net addition of claims are required, beyond those which may otherwise be provided for in documents accompanying this paper. However, in the event that any additional fees required for consideration of this paper (including fees for net addition of claims) are authorized to be charged to our Deposit Account No. 03-1721.

Respectfully submitted,



Nadège M. Lagneau, Ph.D.

Agent for Applicant

Reg. No.: 51,908

Date: July 7, 2004

PATENT GROUP  
CHOATE, HALL & STEWART  
Exchange Place  
53 State Street  
Boston, MA 02109  
Tel: (617) 248-5150  
Fax: (617) 248-4000